Because the U.K. is a perfect launching pad. Because manufacturing is close. Because the UK has 4000 GBM diagnoses per year, which is a more manageable number to start with. Because they already have the specials program treating patients. Orbis often helps coordinate consecutive approval in the member countries.
the continued demise of Novocure's market cap and failed trials are astounding. Its undeniable now that this is correlated to NWBO's upcoming trial data which after Novoc has nothing left to sell.
Market Data 
Markets 
AI
